Search
Desvenlafaxine
go.drugbank.com/drugs/DB06700ApprovedInvestigationalDesvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. … [L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: O-desmethylvenlafaxineCindunistat
go.drugbank.com/drugs/DB20593ExperimentalCindunistat is a small molecule drug. Cindunistat has a monoisotopic molecular weight of 219.1 Da.
Categories: Nitric Oxide Synthase Type II, antagonists & inhibitorsSumatriptan
go.drugbank.com/drugs/DB00669ApprovedInvestigationalSumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches. … [L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines.
Mixtures: TRASS® TABLETA RECUBIERTA, TRASS® TABLETA RECUBIERTACategories: P-glycoprotein substrates, Heterocyclic Compounds, 2-RingTisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigationalTF is a novel target for cancers, as it is often overexpressed on solid tumours, including cervical cancer, and it is associated with poor clinical outcomes. … Tisotumab vedotin is a tissue factor-directed antibody-drug conjugate (ADC) comprised of an anti-tissue factor (TF) human IgG1-kappa antibody conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesPericiazine
go.drugbank.com/drugs/DB01608ApprovedPericiazine is a phenothiazine of the piperidine group. … Pericyazine, like other phenothiazines, is presumed to act principally in the subcortical areas, by producing what has been described as a central adrenergic blockade.
Categories: Heterocyclic Compounds, 3-Ring, Adrenergic alpha-1 Receptor AntagonistsSynonyms: 2-Cyano-10-(3-(4-hydroxy-1-piperidyl)propyl)phenothiazine, Cyano-3 ((hydroxy-4 piperidyl-1)-3 propyl)-10 phenothiazineTrilaciclib
go.drugbank.com/drugs/DB15442ApprovedInvestigationalTrilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing
Categories: MATE 2-K Inhibitors, MATE 1 InhibitorsDurlobactam
go.drugbank.com/drugs/DB16704ApprovedInvestigationalDurlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor. It is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases. … [A263306] It is used to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of _Acinetobacter baumannii-calcoaceticus_
Synonyms: (2S,5R)-2-CARBAMOYL-3-METHYL-7-OXO-1,6-DIAZABICYCLO(3.2.1)OCT-3-EN-6-YL SULFATE, SULFURIC ACID, MONO((2S,5R)-2-(AMINOCARBONYL)-3-METHYL-7-OXO-1,6-DIAZABICYCLO(3.2.1)OCT-3-EN-6-YL) ESTERPasireotide
go.drugbank.com/drugs/DB06663ApprovedInvestigationalPasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsSynonyms: cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)Pegvaliase
go.drugbank.com/drugs/DB12839ApprovedInvestigationalPhenylketonuria is a rare autosomal recessive disorder that is characterized by deficiency of the enzyme phenylalanine hydroxylase (PAH) [A33284] and affects about 1 in 10,000 to 15,000 people in the United … Pegvaliase-pqpz, or PEGylated pegvaliase, is used as a novel enzyme substitution therapy and is marketed as Palynziq for subcutaneous injection.
Daclizumab
go.drugbank.com/drugs/DB00111ApprovedInvestigationalWithdrawnHumanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. … Despite being approved for use, Zinbryta (daclizumab)'s complex pre-existing safety profile consisting of its restricted availability through a Risk Evaluation and Mitigation Strategy program [L1738] and
Categories: Interleukin-2 Receptor Antagonist, Interleukin-2 Receptor Blocking Antibody